Supernus Pharmaceuticals Price to Book Ratio 2011-2024 | SUPN

Historical price to book ratio values for Supernus Pharmaceuticals (SUPN) over the last 10 years. The current price to book ratio for Supernus Pharmaceuticals as of January 23, 2025 is 2.09.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Supernus Pharmaceuticals Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2025-01-23 38.64 2.12
2024-09-30 31.18 $18.24 1.71
2024-06-30 26.75 $17.39 1.54
2024-03-31 34.11 $16.98 2.01
2023-12-31 28.94 $16.84 1.72
2023-09-30 27.57 $16.81 1.64
2023-06-30 30.06 $16.85 1.78
2023-03-31 36.23 $16.81 2.15
2022-12-31 35.67 $16.33 2.18
2022-09-30 33.85 $16.01 2.11
2022-06-30 28.92 $15.80 1.83
2022-03-31 32.32 $15.56 2.08
2021-12-31 29.16 $15.32 1.90
2021-09-30 26.67 $15.33 1.74
2021-06-30 30.79 $14.78 2.08
2021-03-31 26.18 $14.24 1.84
2020-12-31 25.16 $14.09 1.79
2020-09-30 20.84 $13.46 1.55
2020-06-30 23.75 $12.66 1.88
2020-03-31 17.99 $11.68 1.54
2019-12-31 23.72 $11.33 2.09
2019-09-30 27.48 $10.62 2.59
2019-06-30 33.09 $9.97 3.32
2019-03-31 35.04 $9.17 3.82
2018-12-31 33.22 $8.66 3.84
2018-09-30 50.35 $8.07 6.24
2018-06-30 59.85 $7.48 8.00
2018-03-31 45.80 $6.81 6.72
2017-12-31 39.85 $5.21 7.65
2017-09-30 40.00 $4.91 8.15
2017-06-30 43.10 $4.52 9.53
2017-03-31 31.30 $4.10 7.63
2016-12-31 25.25 $3.84 6.58
2016-09-30 24.73 $3.50 7.07
2016-06-30 20.37 $2.23 9.15
2016-03-31 15.25 $1.96 7.76
2015-12-31 13.44 $1.80 7.48
2015-09-30 14.03 $1.61 8.69
2015-06-30 16.98 $1.48 11.45
2015-03-31 12.09 $1.34 9.01
2014-12-31 8.30 $0.95 8.76
2014-09-30 8.69 $0.84 10.36
2014-06-30 10.95 $0.79 13.83
2014-03-31 8.94 $0.69 12.96
2013-12-31 7.54 $0.84 9.01
2013-09-30 7.33 $0.40 18.22
2013-06-30 6.43 $1.16 5.54
2013-03-31 5.62 $1.34 4.21
2012-12-31 7.17 $1.88 3.81
2012-09-30 11.55 $1.01 11.47
2012-06-30 9.36 $1.55 6.03
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.108B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $24.935B 8.18
Dr Reddy's Laboratories (RDY) India $12.596B 24.10
BridgeBio Pharma (BBIO) United States $6.773B 0.00
Bausch Health Cos (BHC) Canada $2.792B 2.06
Amphastar Pharmaceuticals (AMPH) United States $1.738B 10.44
Personalis (PSNL) United States $0.396B 0.00
Taysha Gene Therapies (TSHA) United States $0.314B 21.86
Assembly Biosciences (ASMB) United States $0.095B 0.00
Sol-Gel Technologies (SLGL) Israel $0.025B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00